Literature DB >> 1558795

Porphyrin metabolism in some malignant diseases.

M M el-Sharabasy1, A M el-Waseef, M M Hafez, S A Salim.   

Abstract

Porphyrin metabolism was studied in 21 children of both sexes suffering from acute lymphoblastic leukaemia (ALL) and 34 adult patients of different ages and sexes suffering from ALL (n = 14), non-Hodgkin's lymphoma (NHL), n = 14, or Hodgkin's disease (HD), n = 6. In addition, two groups of healthy children (n = 14), and adults (n = 17) were studied for comparison. It was apparent from this study that the activity of uroporphyrinogen-1-synthetase (URO-1-S, E.C. 4.3.1.8) was highly significantly activated in the blood of children, while the activities of blood 5-aminolevulinic acid dehydrase (E.C. 4.2.1.24) and ferrochelatase (E.C. 4.99.1.1.), as expressed by protoporphyrin/haem ratio, were inhibited in those children. Also, free erythrocyte total porphyrins were increased, while the haem content was reduced. The concentrations of 5-aminolevulinic acid, coproporphyprin and uroporphyrin were increased in the urine of children with ALL. On the other hand, some dramatic changes were found in porphyrin metabolism in adult patients suffering from ALL, NHL and HD. The aforementioned disturbances were discussed in the light of some factors which may affect the enzymatic activities in the synthesis of porphyrins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1558795      PMCID: PMC1977583          DOI: 10.1038/bjc.1992.83

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  [PORPHYRIN BIOSYNTHESIS IN LEUKOCYTES].

Authors:  A VANNOTTI; F JEUNET
Journal:  Schweiz Med Wochenschr       Date:  1963-09-07

2.  Studies on porphyrin biosynthesis in lead-intoxicated rabbits.

Authors:  L C San Martín de Viale; R W de Calmanovici; M C Ríos de Molina; M Grinstein
Journal:  Clin Chim Acta       Date:  1976-06-15       Impact factor: 3.786

3.  Simple method for determination of urinary -aminolevulinic acid as an index of lead exposure.

Authors:  K Tomokuni; M Ogata
Journal:  Clin Chem       Date:  1972-12       Impact factor: 8.327

4.  The porphyrias: clinical chemistry, diagnosis and methodology.

Authors:  G H Elder
Journal:  Clin Haematol       Date:  1980-06

5.  Heme biosynthesis in Friend erythroleukemia cells: control by ferrochelatase.

Authors:  T Rutherford; G G Thompson; M R Moore
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

6.  Erythrocyte uroporphyrinogen synthase activity as a possible diagnostic aid in the diagnosis of lymphoproliferative diseases.

Authors:  O Epstein; M Lahav; N Schoenfeld; L Nemesh; M Shaklai; A Atsmon
Journal:  Cancer       Date:  1983-09-01       Impact factor: 6.860

7.  Erythrocyte protoporphyrin/heme ratio in the assessment of iron status.

Authors:  R F Labbé; C A Finch; N J Smith; R N Doan; S K Sood; N Madan
Journal:  Clin Chem       Date:  1979-01       Impact factor: 8.327

8.  delta-Aminolevulinate dehydratase in human erythroleukemia cells: an immunologically distinct enzyme.

Authors:  C S Chang; S Sassa
Journal:  Blood       Date:  1985-04       Impact factor: 22.113

9.  Sequential induction of heme pathway enzymes during erythroid differentiation of mouse Friend leukemia virus-infected cells.

Authors:  S Sassa
Journal:  J Exp Med       Date:  1976-02-01       Impact factor: 14.307

10.  Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins.

Authors:  Z Malik; H Lugaci
Journal:  Br J Cancer       Date:  1987-11       Impact factor: 7.640

View more
  25 in total

1.  Comparison of the uptake of 5-aminolevulinic acid and its methyl ester in keratinocytes and skin.

Authors:  R Schulten; B Novak; B Schmitz; H Lübbert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-17       Impact factor: 3.000

Review 2.  Current concepts in gastrointestinal photodynamic therapy.

Authors:  J Webber; M Herman; D Kessel; D Fromm
Journal:  Ann Surg       Date:  1999-07       Impact factor: 12.969

Review 3.  The value of extent of resection of glioblastomas: clinical evidence and current approach.

Authors:  Joao Paulo Almeida; Kaisorn L Chaichana; Jordina Rincon-Torroella; Alfredo Quinones-Hinojosa
Journal:  Curr Neurol Neurosci Rep       Date:  2015       Impact factor: 5.081

4.  Specific intensity imaging for glioblastoma and neural cell cultures with 5-aminolevulinic acid-derived protoporphyrin IX.

Authors:  Frank Duffner; Rainer Ritz; Dirk Freudenstein; Michael Weller; Klaus Dietz; Johannes Wessels
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

5.  Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.

Authors:  Isabelle Benz-de Bretagne; Noël Zahr; Amélie Le Gouge; Jean-Sébastien Hulot; Caroline Houillier; Khe Hoang-Xuan; Emmanuel Gyan; Séverine Lissandre; Sylvain Choquet; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

6.  Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma.

Authors:  Andrew Pye; Sandra Campbell; Alison Curnow
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-01       Impact factor: 4.553

7.  P2X7 receptor as a novel drug delivery system to increase the entrance of hydrophilic drugs into cells during photodynamic therapy.

Authors:  Paulo Anastácio Furtado Pacheco; Leonardo Braga Gomes Ferreira; Leonardo Mendonça; Dinarte Neto M Ferreira; Juliana Pimenta Salles; Robson Xavier Faria; Pedro Celso Nogueira Teixeira; Luiz Anastacio Alves
Journal:  J Bioenerg Biomembr       Date:  2016-07-15       Impact factor: 2.945

8.  The impact of fluorescence guidance on spinal intradural tumour surgery.

Authors:  Sven O Eicker; Frank W Floeth; Marcel Kamp; Hans-Jakob Steiger; Daniel Hänggi
Journal:  Eur Spine J       Date:  2013-01-10       Impact factor: 3.134

9.  Upregulated heme biosynthesis, an exploitable vulnerability in MYCN-driven leukemogenesis.

Authors:  Yu Fukuda; Yao Wang; Shangli Lian; John Lynch; Shinjiro Nagai; Bruce Fanshawe; Ayten Kandilci; Laura J Janke; Geoffrey Neale; Yiping Fan; Brian P Sorrentino; Martine F Roussel; Gerard Grosveld; John D Schuetz
Journal:  JCI Insight       Date:  2017-08-03

10.  Photodynamic therapy with 5-aminolaevulinic acid and DNA damage: unravelling roles of p53 and ABCG2.

Authors:  I Postiglione; F Barra; S M Aloj; G Palumbo
Journal:  Cell Prolif       Date:  2016-07-07       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.